The association of α4β7 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies
α4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women found that individuals with higher proportions of α4β7 expressing CD4+ T cells were more likely to become infected with HIV, as well as present with fast...
Saved in:
| Published in | EBioMedicine Vol. 62; p. 103102 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.12.2020
Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | α4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women found that individuals with higher proportions of α4β7 expressing CD4+ T cells were more likely to become infected with HIV, as well as present with faster disease progression. It is unknown if this phenomenon is also observed in men who have sex with men (MSM) or people who inject drugs (PWID).
MSM and transgender women who seroconverted as part of the HVTN 505 HIV vaccine trial and PWID who seroconverted during the ALIVE cohort study were selected as cases and matched to HIV-uninfected controls from the same studies (1:1 and 1:3, respectively). Pre-seroconversion PBMC samples from cases and controls in both studies were examined by flow cytometry to measure levels of α4β7 expression on CD4+ T cells. Multivariable conditional logistic regression was used to compare α4β7 expression levels between cases and controls. A Kaplan-Meier curve was used to examine the association of α4β7 expression pre-seroconversion with HIV disease progression.
In MSM and transgender women (n = 103 cases, 103 controls), there was no statistically significant difference in the levels of α4β7 expression on CD4+ T cells between cases and controls (adjusted odds ratio [adjOR] =1.10, 95% confidence interval [CI]=0.94,1.29; p = 0.246). Interestingly, in PWID (n = 49 cases, 143 controls), cases had significantly lower levels of α4β7 expression compared to their matched controls (adjOR = 0.80, 95% CI = 0.68, 0.93; p = 0.004). Among HIV-positive PWID (n = 47), there was no significant association in HIV disease progression in individuals above or below the median level of α4β7 expression (log-rank p = 0.84).
In contrast to findings in heterosexual women, higher α4β7 expression does not predict HIV acquisition or disease progression in PWID or MSM.
This study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The study was also supported by extramural grants from NIAID T32AI102623 (E.U.P.), and UM1AI069470. |
|---|---|
| AbstractList | AbstractBackgroundα4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women found that individuals with higher proportions of α4β7 expressing CD4 + T cells were more likely to become infected with HIV, as well as present with faster disease progression. It is unknown if this phenomenon is also observed in men who have sex with men (MSM) or people who inject drugs (PWID). MethodsMSM and transgender women who seroconverted as part of the HVTN 505 HIV vaccine trial and PWID who seroconverted during the ALIVE cohort study were selected as cases and matched to HIV-uninfected controls from the same studies (1:1 and 1:3, respectively). Pre-seroconversion PBMC samples from cases and controls in both studies were examined by flow cytometry to measure levels of α4β7 expression on CD4 + T cells. Multivariable conditional logistic regression was used to compare α4β7 expression levels between cases and controls. A Kaplan-Meier curve was used to examine the association of α4β7 expression pre-seroconversion with HIV disease progression. FindingsIn MSM and transgender women ( n = 103 cases, 103 controls), there was no statistically significant difference in the levels of α4β7 expression on CD4 + T cells between cases and controls (adjusted odds ratio [adjOR] =1.10, 95% confidence interval [CI]=0.94,1.29; p = 0.246). Interestingly, in PWID ( n = 49 cases, 143 controls), cases had significantly lower levels of α4β7 expression compared to their matched controls (adjOR = 0.80, 95% CI = 0.68, 0.93; p = 0.004). Among HIV-positive PWID ( n = 47), there was no significant association in HIV disease progression in individuals above or below the median level of α4β7 expression (log-rank p = 0.84). InterpretationIn contrast to findings in heterosexual women, higher α4β7 expression does not predict HIV acquisition or disease progression in PWID or MSM. FundingThis study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The study was also supported by extramural grants from NIAID T32AI102623 (E.U.P.), and UM1AI069470. α4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women found that individuals with higher proportions of α4β7 expressing CD4+ T cells were more likely to become infected with HIV, as well as present with faster disease progression. It is unknown if this phenomenon is also observed in men who have sex with men (MSM) or people who inject drugs (PWID). MSM and transgender women who seroconverted as part of the HVTN 505 HIV vaccine trial and PWID who seroconverted during the ALIVE cohort study were selected as cases and matched to HIV-uninfected controls from the same studies (1:1 and 1:3, respectively). Pre-seroconversion PBMC samples from cases and controls in both studies were examined by flow cytometry to measure levels of α4β7 expression on CD4+ T cells. Multivariable conditional logistic regression was used to compare α4β7 expression levels between cases and controls. A Kaplan-Meier curve was used to examine the association of α4β7 expression pre-seroconversion with HIV disease progression. In MSM and transgender women (n = 103 cases, 103 controls), there was no statistically significant difference in the levels of α4β7 expression on CD4+ T cells between cases and controls (adjusted odds ratio [adjOR] =1.10, 95% confidence interval [CI]=0.94,1.29; p = 0.246). Interestingly, in PWID (n = 49 cases, 143 controls), cases had significantly lower levels of α4β7 expression compared to their matched controls (adjOR = 0.80, 95% CI = 0.68, 0.93; p = 0.004). Among HIV-positive PWID (n = 47), there was no significant association in HIV disease progression in individuals above or below the median level of α4β7 expression (log-rank p = 0.84). In contrast to findings in heterosexual women, higher α4β7 expression does not predict HIV acquisition or disease progression in PWID or MSM. This study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The study was also supported by extramural grants from NIAID T32AI102623 (E.U.P.), and UM1AI069470. α4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women found that individuals with higher proportions of α4β7 expressing CD4 T cells were more likely to become infected with HIV, as well as present with faster disease progression. It is unknown if this phenomenon is also observed in men who have sex with men (MSM) or people who inject drugs (PWID). MSM and transgender women who seroconverted as part of the HVTN 505 HIV vaccine trial and PWID who seroconverted during the ALIVE cohort study were selected as cases and matched to HIV-uninfected controls from the same studies (1:1 and 1:3, respectively). Pre-seroconversion PBMC samples from cases and controls in both studies were examined by flow cytometry to measure levels of α4β7 expression on CD4 T cells. Multivariable conditional logistic regression was used to compare α4β7 expression levels between cases and controls. A Kaplan-Meier curve was used to examine the association of α4β7 expression pre-seroconversion with HIV disease progression. In MSM and transgender women (n = 103 cases, 103 controls), there was no statistically significant difference in the levels of α4β7 expression on CD4 T cells between cases and controls (adjusted odds ratio [adjOR] =1.10, 95% confidence interval [CI]=0.94,1.29; p = 0.246). Interestingly, in PWID (n = 49 cases, 143 controls), cases had significantly lower levels of α4β7 expression compared to their matched controls (adjOR = 0.80, 95% CI = 0.68, 0.93; p = 0.004). Among HIV-positive PWID (n = 47), there was no significant association in HIV disease progression in individuals above or below the median level of α4β7 expression (log-rank p = 0.84). In contrast to findings in heterosexual women, higher α4β7 expression does not predict HIV acquisition or disease progression in PWID or MSM. This study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The study was also supported by extramural grants from NIAID T32AI102623 (E.U.P.), and UM1AI069470. Background: α4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women found that individuals with higher proportions of α4β7 expressing CD4+ T cells were more likely to become infected with HIV, as well as present with faster disease progression. It is unknown if this phenomenon is also observed in men who have sex with men (MSM) or people who inject drugs (PWID). Methods: MSM and transgender women who seroconverted as part of the HVTN 505 HIV vaccine trial and PWID who seroconverted during the ALIVE cohort study were selected as cases and matched to HIV-uninfected controls from the same studies (1:1 and 1:3, respectively). Pre-seroconversion PBMC samples from cases and controls in both studies were examined by flow cytometry to measure levels of α4β7 expression on CD4+ T cells. Multivariable conditional logistic regression was used to compare α4β7 expression levels between cases and controls. A Kaplan-Meier curve was used to examine the association of α4β7 expression pre-seroconversion with HIV disease progression. Findings: In MSM and transgender women (n = 103 cases, 103 controls), there was no statistically significant difference in the levels of α4β7 expression on CD4+ T cells between cases and controls (adjusted odds ratio [adjOR] =1.10, 95% confidence interval [CI]=0.94,1.29; p = 0.246). Interestingly, in PWID (n = 49 cases, 143 controls), cases had significantly lower levels of α4β7 expression compared to their matched controls (adjOR = 0.80, 95% CI = 0.68, 0.93; p = 0.004). Among HIV-positive PWID (n = 47), there was no significant association in HIV disease progression in individuals above or below the median level of α4β7 expression (log-rank p = 0.84). Interpretation: In contrast to findings in heterosexual women, higher α4β7 expression does not predict HIV acquisition or disease progression in PWID or MSM. Funding: This study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The study was also supported by extramural grants from NIAID T32AI102623 (E.U.P.), and UM1AI069470. α4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women found that individuals with higher proportions of α4β7 expressing CD4+ T cells were more likely to become infected with HIV, as well as present with faster disease progression. It is unknown if this phenomenon is also observed in men who have sex with men (MSM) or people who inject drugs (PWID).BACKGROUNDα4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women found that individuals with higher proportions of α4β7 expressing CD4+ T cells were more likely to become infected with HIV, as well as present with faster disease progression. It is unknown if this phenomenon is also observed in men who have sex with men (MSM) or people who inject drugs (PWID).MSM and transgender women who seroconverted as part of the HVTN 505 HIV vaccine trial and PWID who seroconverted during the ALIVE cohort study were selected as cases and matched to HIV-uninfected controls from the same studies (1:1 and 1:3, respectively). Pre-seroconversion PBMC samples from cases and controls in both studies were examined by flow cytometry to measure levels of α4β7 expression on CD4+ T cells. Multivariable conditional logistic regression was used to compare α4β7 expression levels between cases and controls. A Kaplan-Meier curve was used to examine the association of α4β7 expression pre-seroconversion with HIV disease progression.METHODSMSM and transgender women who seroconverted as part of the HVTN 505 HIV vaccine trial and PWID who seroconverted during the ALIVE cohort study were selected as cases and matched to HIV-uninfected controls from the same studies (1:1 and 1:3, respectively). Pre-seroconversion PBMC samples from cases and controls in both studies were examined by flow cytometry to measure levels of α4β7 expression on CD4+ T cells. Multivariable conditional logistic regression was used to compare α4β7 expression levels between cases and controls. A Kaplan-Meier curve was used to examine the association of α4β7 expression pre-seroconversion with HIV disease progression.In MSM and transgender women (n = 103 cases, 103 controls), there was no statistically significant difference in the levels of α4β7 expression on CD4+ T cells between cases and controls (adjusted odds ratio [adjOR] =1.10, 95% confidence interval [CI]=0.94,1.29; p = 0.246). Interestingly, in PWID (n = 49 cases, 143 controls), cases had significantly lower levels of α4β7 expression compared to their matched controls (adjOR = 0.80, 95% CI = 0.68, 0.93; p = 0.004). Among HIV-positive PWID (n = 47), there was no significant association in HIV disease progression in individuals above or below the median level of α4β7 expression (log-rank p = 0.84).FINDINGSIn MSM and transgender women (n = 103 cases, 103 controls), there was no statistically significant difference in the levels of α4β7 expression on CD4+ T cells between cases and controls (adjusted odds ratio [adjOR] =1.10, 95% confidence interval [CI]=0.94,1.29; p = 0.246). Interestingly, in PWID (n = 49 cases, 143 controls), cases had significantly lower levels of α4β7 expression compared to their matched controls (adjOR = 0.80, 95% CI = 0.68, 0.93; p = 0.004). Among HIV-positive PWID (n = 47), there was no significant association in HIV disease progression in individuals above or below the median level of α4β7 expression (log-rank p = 0.84).In contrast to findings in heterosexual women, higher α4β7 expression does not predict HIV acquisition or disease progression in PWID or MSM.INTERPRETATIONIn contrast to findings in heterosexual women, higher α4β7 expression does not predict HIV acquisition or disease progression in PWID or MSM.This study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The study was also supported by extramural grants from NIAID T32AI102623 (E.U.P.), and UM1AI069470.FUNDINGThis study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The study was also supported by extramural grants from NIAID T32AI102623 (E.U.P.), and UM1AI069470. |
| ArticleNumber | 103102 |
| Author | Cicala, Claudia Kirby, Charles Corey, Lawrence Redd, Andrew D. Sobieszczyk, Magdalena E. Patel, Eshan U. Astemborski, Jacquie Mehta, Shruti H. Martin, Alyssa R. Kirk, Gregory D. Hammer, Scott M. Janes, Holly Clayton, Ashley Marshall, Kyle Quinn, Thomas C. Arthos, James |
| Author_xml | – sequence: 1 givenname: Alyssa R. surname: Martin fullname: Martin, Alyssa R. organization: Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States – sequence: 2 givenname: Eshan U. surname: Patel fullname: Patel, Eshan U. organization: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States – sequence: 3 givenname: Charles surname: Kirby fullname: Kirby, Charles organization: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States – sequence: 4 givenname: Jacquie surname: Astemborski fullname: Astemborski, Jacquie organization: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 5 givenname: Gregory D. surname: Kirk fullname: Kirk, Gregory D. organization: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 6 givenname: Shruti H. surname: Mehta fullname: Mehta, Shruti H. organization: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 7 givenname: Kyle surname: Marshall fullname: Marshall, Kyle organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States – sequence: 8 givenname: Holly surname: Janes fullname: Janes, Holly organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States – sequence: 9 givenname: Ashley surname: Clayton fullname: Clayton, Ashley organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States – sequence: 10 givenname: Lawrence surname: Corey fullname: Corey, Lawrence organization: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States – sequence: 11 givenname: Scott M. surname: Hammer fullname: Hammer, Scott M. organization: Department of Medicine, Columbia University Medical Center, New York, NY, United States – sequence: 12 givenname: Magdalena E. surname: Sobieszczyk fullname: Sobieszczyk, Magdalena E. organization: Department of Medicine, Columbia University Medical Center, New York, NY, United States – sequence: 13 givenname: James surname: Arthos fullname: Arthos, James organization: Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States – sequence: 14 givenname: Claudia surname: Cicala fullname: Cicala, Claudia organization: Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States – sequence: 15 givenname: Andrew D. orcidid: 0000-0003-4651-1423 surname: Redd fullname: Redd, Andrew D. email: aredd2@jhmi.edu, reddandrew@niaid.nih.gov organization: Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States – sequence: 16 givenname: Thomas C. surname: Quinn fullname: Quinn, Thomas C. organization: Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33166790$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks1u1DAUhSNUREvpEyAhL9nM4L_ECYhKaAR0pEosKGwtj3Mz45CxUzuZtm_DK8CD9Jlwkha1laCrJMfnfFfOPc-TPessJMlLgucEk-xNPYeVcds5xXRQGMH0SXJAWUpnrMj43p33_eQohBpjTFIexfxZss8YyTJR4IPk59kGkArBaaM64yxyFbr-xa9_CwSXrYcQBvHCdBt0svyOlD7vTTCjU9kSlSaACoBa79a3ZmNRC65tAF1sXPyqQXeo9P06jJEt2PFgo3aAAlxO8Ki-RYsBpZ3tvGtQ6PrSQHiRPK1UE-Do5nmYfPv08WxxMjv98nm5-HA601wIOstzlvGUaJFSrlOdFzkhtAIBtKJ5SXGaCUqKEgqaMaVVQfOMRCeFVBV4pVJ2mCwnbulULVtvtspfSaeMHAXn11L5zugGpGCZqDQnTGHFFWcrQYCLyFYVJtWqiKzjidX2qy2UGuKNVHMPev_Emo1cu50UWZpnfAC8vgF4d95D6OTWBA1Noyy4PkjK04LxQuDB-ururL9DblccDcVk0N6F4KGS2nTjruNo00iC5dAoWcuxUXJolJwaFbPsQfYW___U-ykFcV87A14GbcBqKI2PXYg_1DySP36Q142xRqvmB1xBqF3vbayCJDJQieXXoelD0SlmmIucRcC7fwMeHf8HQ0oQ1Q |
| CitedBy_id | crossref_primary_10_1111_hiv_13254 crossref_primary_10_1016_j_ebiom_2020_103148 crossref_primary_10_1093_infdis_jiae638 |
| Cites_doi | 10.1056/NEJMoa1310566 10.1126/scitranslmed.aam6354 10.1136/gut.37.4.524 10.1093/oxfordjournals.aje.a115727 10.1126/science.aaw7765 10.1126/science.aaw8562 10.1001/archinte.161.10.1281 10.1073/pnas.0907898106 10.1126/scitranslmed.aax3447 10.1038/mi.2015.28 10.1371/journal.pone.0238234 10.1097/01.qai.0000243050.27580.1a 10.1002/eji.1830260427 10.1038/nm.3715 10.1093/infdis/jis342 10.1073/pnas.0911796106 10.1083/jcb.201110023 10.1097/COH.0b013e3283504941 10.1084/jem.20041196 10.1126/science.aag1276 10.1126/science.aav6695 10.1186/1471-2172-5-13 |
| ContentType | Journal Article |
| Copyright | 2020 Published by Elsevier B.V. |
| Copyright_xml | – notice: 2020 – notice: Published by Elsevier B.V. |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.ebiom.2020.103102 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2352-3964 |
| EndPage | 103102 |
| ExternalDocumentID | oai_doaj_org_article_7367fc413a0a4a43b71e47de9af01fb9 PMC7658649 33166790 10_1016_j_ebiom_2020_103102 S2352396420304783 1_s2_0_S2352396420304783 |
| Genre | Journal Article |
| GrantInformation | This study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The study was also supported by extramural grants from NIAID T32AI102623 (E.U.P.), and UM1AI069470. |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: UM1 AI068635 |
| GroupedDBID | .1- .FO 0R~ 4.4 457 53G 5VS AAEDT AAEDW AAIKJ AALRI AAMRU AAXUO AAYWO ABMAC ACGFS ACVFH ADBBV ADCNI ADEZE ADRAZ ADVLN AEUPX AEXQZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BCNDV EBS EJD FDB GROUPED_DOAJ HYE HZ~ IPNFZ KQ8 M41 M48 O9- OK1 RIG ROL RPM SSZ Z5R 0SF 6I. AACTN AAFTH AFCTW NCXOZ AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c4772-8836451c7524c5c898112fe7e2f28d20567219de9263aca9286124c2e5a90ba53 |
| IEDL.DBID | M48 |
| ISSN | 2352-3964 |
| IngestDate | Wed Aug 27 01:26:55 EDT 2025 Thu Aug 21 18:29:56 EDT 2025 Thu Jul 10 21:58:45 EDT 2025 Thu Jan 02 22:57:02 EST 2025 Thu Apr 24 22:54:44 EDT 2025 Tue Jul 01 00:38:56 EDT 2025 Tue Jul 25 20:59:08 EDT 2023 Sun Feb 23 10:19:23 EST 2025 Tue Aug 26 16:33:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open access article under the CC BY license. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4772-8836451c7524c5c898112fe7e2f28d20567219de9263aca9286124c2e5a90ba53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ADR and TCQ contributed equally to this manuscript. |
| ORCID | 0000-0003-4651-1423 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1016/j.ebiom.2020.103102 |
| PMID | 33166790 |
| PQID | 2459349709 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7367fc413a0a4a43b71e47de9af01fb9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7658649 proquest_miscellaneous_2459349709 pubmed_primary_33166790 crossref_citationtrail_10_1016_j_ebiom_2020_103102 crossref_primary_10_1016_j_ebiom_2020_103102 elsevier_sciencedirect_doi_10_1016_j_ebiom_2020_103102 elsevier_clinicalkeyesjournals_1_s2_0_S2352396420304783 elsevier_clinicalkey_doi_10_1016_j_ebiom_2020_103102 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-Dec |
| PublicationDateYYYYMMDD | 2020-12-01 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-Dec |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | EBioMedicine |
| PublicationTitleAlternate | EBioMedicine |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Yu (bib0001) 2012; 196 Martin (bib0022) 2020; 15 Joag (bib0003) 2016; 9 Byrareddy (bib0007) 2014; 20 Di Mascio (bib0010) 2019; 365 Sivro (bib0013) 2018; 10 Abbink (bib0011) 2019; 365 Rodriguez, Paquet, Yang, Erle (bib0017) 2004; 5 Vlahov (bib0015) 1990; 132 Andrew, Rott, Kilshaw, Butcher (bib0016) 1996; 26 Mehandru (bib0005) 2004; 200 Cicala (bib0002) 2009; 106 Sneller (bib0012) 2019; 11 Hammer (bib0014) 2013; 369 McKinnon, Kaul (bib0006) 2012; 7 Mehta (bib0021) 2006; 43 Benlahrech (bib0020) 2009; 106 Duerr (bib0019) 2012; 206 Iwamoto (bib0009) 2019; 365 Strathdee (bib0018) 2001; 161 Schneider (bib0004) 1995; 37 Byrareddy (bib0008) 2016; 354 Cicala (10.1016/j.ebiom.2020.103102_bib0002) 2009; 106 Joag (10.1016/j.ebiom.2020.103102_bib0003) 2016; 9 Iwamoto (10.1016/j.ebiom.2020.103102_bib0009) 2019; 365 Di Mascio (10.1016/j.ebiom.2020.103102_bib0010) 2019; 365 Martin (10.1016/j.ebiom.2020.103102_bib0022) 2020; 15 Sivro (10.1016/j.ebiom.2020.103102_bib0013) 2018; 10 Schneider (10.1016/j.ebiom.2020.103102_bib0004) 1995; 37 Andrew (10.1016/j.ebiom.2020.103102_bib0016) 1996; 26 Abbink (10.1016/j.ebiom.2020.103102_bib0011) 2019; 365 Strathdee (10.1016/j.ebiom.2020.103102_bib0018) 2001; 161 Byrareddy (10.1016/j.ebiom.2020.103102_bib0007) 2014; 20 Hammer (10.1016/j.ebiom.2020.103102_bib0014) 2013; 369 Vlahov (10.1016/j.ebiom.2020.103102_bib0015) 1990; 132 Sneller (10.1016/j.ebiom.2020.103102_bib0012) 2019; 11 Mehandru (10.1016/j.ebiom.2020.103102_bib0005) 2004; 200 Yu (10.1016/j.ebiom.2020.103102_bib0001) 2012; 196 Rodriguez (10.1016/j.ebiom.2020.103102_bib0017) 2004; 5 Mehta (10.1016/j.ebiom.2020.103102_bib0021) 2006; 43 Byrareddy (10.1016/j.ebiom.2020.103102_bib0008) 2016; 354 Duerr (10.1016/j.ebiom.2020.103102_bib0019) 2012; 206 Benlahrech (10.1016/j.ebiom.2020.103102_bib0020) 2009; 106 McKinnon (10.1016/j.ebiom.2020.103102_bib0006) 2012; 7 |
| References_xml | – volume: 365 start-page: 1025 year: 2019 end-page: 1029 ident: bib0010 article-title: Evaluation of an antibody to alpha4beta7 in the control of SIVmac239-nef-stop infection publication-title: Science – volume: 9 start-page: 1 year: 2016 end-page: 12 ident: bib0003 article-title: Identification of preferential CD4+ T-cell targets for HIV infection in the cervix publication-title: Mucosal Immunol – volume: 37 start-page: 524 year: 1995 end-page: 529 ident: bib0004 article-title: Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group publication-title: Gut – volume: 365 start-page: 1033 year: 2019 end-page: 1036 ident: bib0009 article-title: Blocking alpha4beta7 integrin binding to SIV does not improve virologic control publication-title: Science – volume: 106 start-page: 20877 year: 2009 end-page: 20882 ident: bib0002 article-title: The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1 publication-title: Proc Natl Acad Sci USA – volume: 15 year: 2020 ident: bib0022 article-title: Racial differences in α4β7 expression on CD4+ T cells of HIV-negative men and women who inject drugs publication-title: PLoS One – volume: 132 start-page: 847 year: 1990 end-page: 856 ident: bib0015 article-title: Association of drug injection patterns with antibody to human immunodeficiency virus type 1 among intravenous drug users in Baltimore, Maryland publication-title: Am J Epidemiol – volume: 206 start-page: 258 year: 2012 end-page: 266 ident: bib0019 article-title: Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study) publication-title: J Infect Dis – volume: 26 start-page: 897 year: 1996 end-page: 905 ident: bib0016 article-title: Distribution of α4β7 and αEβ7 integrins on thymocytes, intestinal epithelial lymphocytes and peripheral lymphocytes publication-title: Eur J Immunol – volume: 11 year: 2019 ident: bib0012 article-title: An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals publication-title: Sci Transl Med – volume: 10 year: 2018 ident: bib0013 article-title: Integrin alpha4beta7 expression on peripheral blood CD4(+) T cells predicts HIV acquisition and disease progression outcomes publication-title: Sci Transl Med – volume: 365 start-page: 1029 year: 2019 end-page: 1033 ident: bib0011 article-title: Lack of therapeutic efficacy of an antibody to alpha4beta7 in SIVmac251-infected rhesus macaques publication-title: Science – volume: 20 start-page: 1397 year: 2014 end-page: 1400 ident: bib0007 article-title: Targeting alpha4beta7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection publication-title: Nat Med – volume: 5 year: 2004 ident: bib0017 article-title: Differential gene expression by integrin β7+ and β7- memory T helper cells publication-title: BMC Immunol – volume: 196 start-page: 131 year: 2012 end-page: 146 ident: bib0001 article-title: Structural specializations of α 4β 7, an integrin that mediates rolling adhesion publication-title: J Cell Biol – volume: 354 start-page: 197 year: 2016 end-page: 202 ident: bib0008 article-title: Sustained virologic control in SIV+ macaques after antiretroviral and alpha4beta7 antibody therapy publication-title: Science – volume: 43 start-page: 368 year: 2006 end-page: 372 ident: bib0021 article-title: HIV incidence among injection drug users in Baltimore, Maryland (1988–2004) publication-title: J Acquir Immune Defic Syndr – volume: 200 start-page: 761 year: 2004 end-page: 770 ident: bib0005 article-title: Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract publication-title: J Exp Med – volume: 369 start-page: 2083 year: 2013 end-page: 2092 ident: bib0014 article-title: Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine publication-title: N Engl J Med – volume: 161 start-page: 1281 year: 2001 end-page: 1288 ident: bib0018 article-title: Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective publication-title: Arch Intern Med – volume: 106 start-page: 19940 year: 2009 end-page: 19945 ident: bib0020 article-title: Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 publication-title: Proc Natl Acad Sci USA – volume: 7 start-page: 195 year: 2012 end-page: 202 ident: bib0006 article-title: Quality and quantity: mucosal CD4+ T cells and HIV susceptibility publication-title: Curr Opin. HIV AIDS – volume: 369 start-page: 2083 year: 2013 ident: 10.1016/j.ebiom.2020.103102_bib0014 article-title: Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa1310566 – volume: 10 year: 2018 ident: 10.1016/j.ebiom.2020.103102_bib0013 article-title: Integrin alpha4beta7 expression on peripheral blood CD4(+) T cells predicts HIV acquisition and disease progression outcomes publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aam6354 – volume: 37 start-page: 524 year: 1995 ident: 10.1016/j.ebiom.2020.103102_bib0004 article-title: Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group publication-title: Gut doi: 10.1136/gut.37.4.524 – volume: 132 start-page: 847 year: 1990 ident: 10.1016/j.ebiom.2020.103102_bib0015 article-title: Association of drug injection patterns with antibody to human immunodeficiency virus type 1 among intravenous drug users in Baltimore, Maryland publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a115727 – volume: 365 start-page: 1033 year: 2019 ident: 10.1016/j.ebiom.2020.103102_bib0009 article-title: Blocking alpha4beta7 integrin binding to SIV does not improve virologic control publication-title: Science doi: 10.1126/science.aaw7765 – volume: 365 start-page: 1029 year: 2019 ident: 10.1016/j.ebiom.2020.103102_bib0011 article-title: Lack of therapeutic efficacy of an antibody to alpha4beta7 in SIVmac251-infected rhesus macaques publication-title: Science doi: 10.1126/science.aaw8562 – volume: 161 start-page: 1281 year: 2001 ident: 10.1016/j.ebiom.2020.103102_bib0018 article-title: Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective publication-title: Arch Intern Med doi: 10.1001/archinte.161.10.1281 – volume: 106 start-page: 19940 year: 2009 ident: 10.1016/j.ebiom.2020.103102_bib0020 article-title: Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0907898106 – volume: 11 year: 2019 ident: 10.1016/j.ebiom.2020.103102_bib0012 article-title: An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aax3447 – volume: 9 start-page: 1 year: 2016 ident: 10.1016/j.ebiom.2020.103102_bib0003 article-title: Identification of preferential CD4+ T-cell targets for HIV infection in the cervix publication-title: Mucosal Immunol doi: 10.1038/mi.2015.28 – volume: 15 year: 2020 ident: 10.1016/j.ebiom.2020.103102_bib0022 article-title: Racial differences in α4β7 expression on CD4+ T cells of HIV-negative men and women who inject drugs publication-title: PLoS One doi: 10.1371/journal.pone.0238234 – volume: 43 start-page: 368 year: 2006 ident: 10.1016/j.ebiom.2020.103102_bib0021 article-title: HIV incidence among injection drug users in Baltimore, Maryland (1988–2004) publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000243050.27580.1a – volume: 26 start-page: 897 year: 1996 ident: 10.1016/j.ebiom.2020.103102_bib0016 article-title: Distribution of α4β7 and αEβ7 integrins on thymocytes, intestinal epithelial lymphocytes and peripheral lymphocytes publication-title: Eur J Immunol doi: 10.1002/eji.1830260427 – volume: 20 start-page: 1397 year: 2014 ident: 10.1016/j.ebiom.2020.103102_bib0007 article-title: Targeting alpha4beta7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection publication-title: Nat Med doi: 10.1038/nm.3715 – volume: 206 start-page: 258 year: 2012 ident: 10.1016/j.ebiom.2020.103102_bib0019 article-title: Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study) publication-title: J Infect Dis doi: 10.1093/infdis/jis342 – volume: 106 start-page: 20877 year: 2009 ident: 10.1016/j.ebiom.2020.103102_bib0002 article-title: The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0911796106 – volume: 196 start-page: 131 year: 2012 ident: 10.1016/j.ebiom.2020.103102_bib0001 article-title: Structural specializations of α 4β 7, an integrin that mediates rolling adhesion publication-title: J Cell Biol doi: 10.1083/jcb.201110023 – volume: 7 start-page: 195 year: 2012 ident: 10.1016/j.ebiom.2020.103102_bib0006 article-title: Quality and quantity: mucosal CD4+ T cells and HIV susceptibility publication-title: Curr Opin. HIV AIDS doi: 10.1097/COH.0b013e3283504941 – volume: 200 start-page: 761 year: 2004 ident: 10.1016/j.ebiom.2020.103102_bib0005 article-title: Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract publication-title: J Exp Med doi: 10.1084/jem.20041196 – volume: 354 start-page: 197 year: 2016 ident: 10.1016/j.ebiom.2020.103102_bib0008 article-title: Sustained virologic control in SIV+ macaques after antiretroviral and alpha4beta7 antibody therapy publication-title: Science doi: 10.1126/science.aag1276 – volume: 365 start-page: 1025 year: 2019 ident: 10.1016/j.ebiom.2020.103102_bib0010 article-title: Evaluation of an antibody to alpha4beta7 in the control of SIVmac239-nef-stop infection publication-title: Science doi: 10.1126/science.aav6695 – volume: 5 year: 2004 ident: 10.1016/j.ebiom.2020.103102_bib0017 article-title: Differential gene expression by integrin β7+ and β7- memory T helper cells publication-title: BMC Immunol doi: 10.1186/1471-2172-5-13 |
| SSID | ssj0001542358 |
| Score | 2.1702187 |
| Snippet | α4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women found that... AbstractBackgroundα4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African... Background: α4β7 is a gut-homing integrin heterodimer that can act as a non-essential binding molecule for HIV. A previous study in heterosexual African women... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 103102 |
| SubjectTerms | Advanced Basic Science Internal Medicine Research Paper |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLVQJSQ2iDfDS0ZiSUTiZ8yuVFQDCzZQ1J3lOA4ziGag6UD5m_5C-yH9Ju61nWEGULthNZrEdmKfE_vaPveakGfeSWM0ap6EawrhZVeYDgAxolHSKY_enKi2eKeme-LtvtxfO-oLNWEpPHBquBeaK9156Gpd6YQTvNFVELoNxnVl1TXRdQ_GvLXJVPIPFugDGk-Wk6zgRokx5FAUdwV0bofZIYte51VeVBmHpRi9f2N0-tv6_FNEuTYq7d4g17M5SbdTNW6SK6G_Ra6mAyZ_3iYnwALqfiNAFx09PxXnZ5qG4yyB7SmuxdLpm4_U-W_LeRJxUde3NO_e0CjiyonnPU2qc_pjtoB_uI5D28PlpyFmOQh9vDFz3wMdwnEqHK6-pDtYVJbG0yHpF--Qvd3XH3amRT6TofACDPGirnHfsvJaMgDW16YGg60LOrCO1S0DcwqmlAbgYYo77wyrwYQSngXpTNk4ye-SrX7Rh_uEAnjKlbqTjQnCtPjDy6BKw1ttat5MCBshsT4HLMdzM77YUZn22UYcLeJoE44T8nyV6WuK13Fx8leI9SopBtuOF4CCNlPQXkbBCREjU-zozwo9MBQ0v_jZ-l_ZwpB7kcFWdmC2tO-Rw0hhhvvYuuYTolY5s6GUDKDLH_l0JLKFbgT3hlwfFsvBMiENF_DVQm3uJWKvGoXzSiltSnjhDcpvtNrmnX4-i6HKNRi4SpgH_6OZH5JrWJWkJXpEto4Ol-ExWIRHzZP48f8Cc5lexQ priority: 102 providerName: Directory of Open Access Journals |
| Title | The association of α4β7 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2352396420304783 https://www.clinicalkey.es/playcontent/1-s2.0-S2352396420304783 https://dx.doi.org/10.1016/j.ebiom.2020.103102 https://www.ncbi.nlm.nih.gov/pubmed/33166790 https://www.proquest.com/docview/2459349709 https://pubmed.ncbi.nlm.nih.gov/PMC7658649 https://doaj.org/article/7367fc413a0a4a43b71e47de9af01fb9 |
| Volume | 62 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dbtMwFLamISRuEP-UwWQkLglKbMeOJyEEE1MBgYSgaHeW4zhrp5GyZoXubXgFeJA9E-fYSUehGuImURLbiX2O48_2d84h5JGzudYKOU_ClolweZ3oGgSiRSlzKx1acyLb4p0cjsTr_Xx_g_RRUbsGbNdO7TCe1Gh29GRxfPoMOvzTc66WR1t1mOyxYESeoXPJSzA0KQxp8LbD-9FsWKBpaAg4l7OEayl6T0Try1kZrYJT_5VB629Q-ie38rfBau8audqhTPo8qsV1suGbG-RyjDt5epN8B-Wg9lwwdFrTsx_i7KeiftExYxuKS7R0-OoTte54PoncLmqbinabOjRwu7rEk4ZGMjr9Np7CFS7v0Go2P2hDls--CQ_G9qunrV_EwuHuDt3FojrGPG0jrfEWGe29_Lg7TLpQDYkTgM-TosDtzMypnIG8XaELwHG1V57VrKgYoCyYaerKaya5dVazApCVcMznVqelzfltstlMG3-X0LrU0qaqzkvtha7wxFMvU80rpQteDgjrRWJc58ccw2kcmZ6wdmiCHA3K0UQ5DsjjZaYv0Y3HxclfoKyXSdEHd7gxnR2YrksbxaWqHYAAm1phBS9V5oWCOto6zaAWAyJ6TTG9mSv8mKGgycXvVuuy-bbvGyYzLTOp-YA6jCrMcHtbFXxA5DJnh58iLvr3Kx_2imzg74JbRrbx03lrmMg1F9CZoTZ3omIvG4XzTEqlU_jgFZVfabXVJ81kHDyYK8C9Uuh7_yeVLXIFryKZ6D7ZPJnN_QOAhCfldlhKgeOb98V26PK_AHMpYPI |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+association+of+%CE%B14%CE%B27+expression+with+HIV+acquisition+and+disease+progression+in+people+who+inject+drugs+and+men+who+have+sex+with+men%3A+Case+control+studies&rft.jtitle=EBioMedicine&rft.au=Martin%2C+Alyssa+R.&rft.au=Patel%2C+Eshan+U.&rft.au=Kirby%2C+Charles&rft.au=Astemborski%2C+Jacquie&rft.date=2020-12-01&rft.issn=2352-3964&rft.eissn=2352-3964&rft.volume=62&rft.spage=103102&rft_id=info:doi/10.1016%2Fj.ebiom.2020.103102&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_ebiom_2020_103102 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F23523964%2FS2352396420X00120%2Fcov150h.gif |